Entering text into the input field will update the search result below

NewLink earns $20M milestone from Merck for Ebola vaccine candidate

Feb. 19, 2015 9:25 AM ETMerck & Co., Inc. (MRK) StockMRK, LUMOBy: Douglas W. House, SA News Editor
  • The initiation of a clinical trial evaluating the rVSV-EBOV (Ebola) vaccine triggers a $20M milestone payment from Merck (NYSE:MRK) to NewLink Genetics (NASDAQ:NLNK).
  • The rVSV-EBOV vaccine candidate, originally developed by the Public Health Agency of Canada, was licensed by NewLInk subsidiary BioProtection Systems. It was exclusively licensed to Merck on November 24, 2014.

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.